Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with first-line cisplatin-based chemotherapy: A retrospective analysis of single institution

Journal of B.U.ON.

Volumn 17, Issue 3, 2012, Pages 533-536

  Inal, Ali ^a   Kaplan, M A ^a   Kucukoner, M ^a   Karakus, A ^a   Isikdogan, A ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Advanced lung cancer; Cisplatin based chemotherapy; Elderly patients; Prognostic factors; Survival

Indexed keywords

ALBUMIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ASSESSMENT TOOL; COMORBIDITY; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84867535247     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488. (Pubitemid 40458328)
2. Shepherd FA. Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol 1993; 5: 310-322. (Pubitemid 23111775)
3. Hotta K, Fujiwara Y, Kiura K et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thoracic Oncol 2007; 2: 402-407. (Pubitemid 47181694)
4. Havlik RJ, Yancik R, Long S, Ries L, Edwards B. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994; 74: 2101-2106. (Pubitemid 24304381)
5. Maione P, Rossi A, Sacco PC et al. Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol 2010;2:251-260.
6. Repetto L, Venturino A, Fratino L et al. Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 2003; 39: 870-880. (Pubitemid 36428618)
7. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91: 66-72.
8. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003; 98: 779-788. (Pubitemid 36959275)
9. Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592 randomized trial. J Natl Cancer Inst 2002; 94: 173-181. (Pubitemid 34162751)
10. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005; 104: 2766-2774. (Pubitemid 41798287)
11. Kelly K, Giarritta S, Akerley W. Should older patients (Pts) receive combination chemotherapy for advanced stage Non-Small Cell Lung Cancer (NSCLC)? An Analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 2001; 20 (abstr 1313).
12. Syrigos KN, Vansteenkiste J, Parikh P et al. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol 2010; 21: 556-561.
13. Oven Ustaalioglu BB, Gumus M, Bilici A et al. Is there a cut-off value for standardized uptake values in positron emission tomography for predicting response to treatment and survival in patients with advanced non-small cell lung cancer? Single center experience. J BUON 2010; 15: 529-536.
14. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122: 1037-1057.
15. Kefeli U, Kaya S, Ustaalioglu BO et al. Prognostic factors in elderly patients with non-small cell lung cancer: a two-center experience. Med Oncol 2011; 28: 661-666.
16. Bunn PA Jr, Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2003; 95: 341-343. (Pubitemid 36395248)
17. Li J, Chen P, Dai CH, Li XQ, Bao QL. Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. Oncology 2009; 76: 355-362.
18. Chen YM, Perng RP, Chen MC, Tsai CM, Ming-Liu J, Whang-Peng J. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. Lung Cancer 2003; 40: 221-226. (Pubitemid 36438724)
19. Kim JG, Ryoo BY, Park YH et al. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 2008; 61: 301-307. (Pubitemid 350160328)
20. Mitry E, Douillard JY, van Cutsem E et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trial. Ann Oncol 2004; 15: 1013-1017. (Pubitemid 39089776)
21. Krishnan S, Rana V, Janjan NA et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 2006; 107: 2589-2596. (Pubitemid 44845612)
22. Soulier JP, Chansky K, Crowley JJ et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008; 3: 457-466. (Pubitemid 351630271)
23. Lilenbaum RC, Herndon J, List M et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: Cancer and Leukaemia Group B (study 9730). J Clin Oncol 2005; 23: 190-196. (Pubitemid 41702638)
24. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372. (Pubitemid 36395256)
25. Frasci G, Lorusso V, Panza N et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced nonsmall-cell lung cancer. J Clin Oncol 2000; 18: 2529-2536. (Pubitemid 30432518)
26. Maione P, Perrone F, Gallo C et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small cell lung cancer receiving chemotherapy: a prognostic analysis of the Multicenter Italian Lung Cancer in the Elderly Study. J Clin Oncol 2005; 23: 6865-6872.
27. Feliu J, López Gfimez L, Madroňal C et al. Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients aged 70 years or older or patients who cannot receive cisplatin. Cancer 1999; 86: 1463-1469. (Pubitemid 29489779)